Caplin Point Laboratories Limited (CAPLIPOINT:NSE) Stock Forecast
Alert
Its only available to paid users.
INR 1,535.00
(+15.01%)
Based on the Caplin Point Laboratories Limited stock forecast from 1 analysts, the average analyst target price for Caplin Point Laboratories Limited is INR 1,535.00 over the next 12 months. Caplin Point Laboratories Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Caplin Point Laboratories Limited is Slightly Bullish , which is based on 8 positive signals and 4 negative signals. At the last closing, Caplin Point Laboratories Limited’s stock price was INR 1,334.70. Caplin Point Laboratories Limited’s stock price has changed by +1.41% over the past week, +5.20% over the past month and +99.31% over the last year.
No recent analyst target price found for Caplin Point Laboratories Limited
No recent average analyst rating found for Caplin Point Laboratories Limited
Company Overview Caplin Point Laboratories Limited
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. It provides liquid and lyophilized vials, pre-filled syringes, 3-pc ophthalmic droppers, pre-mix bags, dry and liquid syrups-bottles, tables, soft gels, capsules, suppositories, liquid and emulsion injectables in ampoules and vials, topicals, and sachets. The company was incorporated in 1990 and is headquartered in Chennai, India. Address: Ashvich Tower, Chennai, India, 600096 Read Less
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. It provides liquid and lyophilized vials, pre-filled syringes, 3-pc ophthalmic dr...Read More
Frequently Asked Questions About Caplin Point Laboratories Limited (CAPLIPOINT:NSE) Stock
Based on ratings from 1 analysts Caplin Point Laboratories Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 1 buy, sell and hold ratings.
CAPLIPOINT:NSE stock's dividend yield is 0.37%.
Our analysis grades CAPLIPOINT:NSE stock's dividend yield at F. This means that CAPLIPOINT:NSE stock's dividend yield is above 36% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this CAPLIPOINT:NSE may be a poor dividend stock for its sector.
Based on targets from 1 analysts, the average taret price for CAPLIPOINT:NSE is INR 1,535.00 over the next 12 months. The maximum analyst target price is INR 1535 while the minimum anlayst target price is INR 1535.
CAPLIPOINT:NSE stock's Price/Earning ratio is 23.31.
Our analysis grades CAPLIPOINT:NSE stock's Price / Earning ratio at C. This means that CAPLIPOINT:NSE stock's Price/Earning ratio is above 24% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this CAPLIPOINT:NSE may be undervalued for its sector.
The last closing price of CAPLIPOINT:NSE's stock was INR 1,334.70.
The most recent market capitalization for CAPLIPOINT:NSE is INR 101.36B.
Based on targets from 1 analysts, the average taret price for CAPLIPOINT:NSE is projected at INR 1,535.00 over the next 12 months.
This means that CAPLIPOINT:NSE's stock price may go up by +15.01% over the next 12 months.
We can't find any ETFs which contains Caplin Point Laboratories Limited's stock.
As per our most recent records Caplin Point Laboratories Limited has 1,642 Employees.
Caplin Point Laboratories Limited's registered address is Ashvich Tower, Chennai, India, 600096.
You can get more information about it from Caplin Point Laboratories Limited's website at https://www.caplinpoint.net.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CAPLIPOINT:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
